Company news

Journey Medical Corporation news in 2022

Journey Medical Corporation's news releases, calls and decks from 2022, newest first.

View company

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic Data for DFD-29Phase 3, registrational studies remain on track for first half of 2023 topline data readout

December 21, 2022

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

December 19, 2022

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

December 4, 2022

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

November 9, 2022

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

November 2, 2022

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

October 3, 2022

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea

August 31, 2022

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

August 29, 2022

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 8, 2022

Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022

August 2, 2022

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA, AMZEEQ and ZILXI Patent Exclusivity

May 25, 2022

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

May 23, 2022

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

May 22, 2022

Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 9, 2022

Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022

May 2, 2022

Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

April 3, 2022

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

March 22, 2022

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

March 17, 2022

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

March 16, 2022

Journey Medical Corporation to Present at the 34th Annual ROTH Conference

March 8, 2022

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation

February 10, 2022

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

January 12, 2022

Calls in 2022